Taletrectinib in TKI-Naïve Patients With ROS1+ NSCLC: Updated Data From TRUST-I and TRUST-II

Lyudmila Bazhenova,¹ Jorge Nieva,² Misako Nagasaka,³ Hidetoshi Hayashi,⁴ Qitao Yu,⁵ Scott Owen,⁶ Maurice Pérol,⁷ Feiwu Ran,⁸ Wei Wang,⁹ Xianyu Zhang,⁸ Wenfeng Chen,⁸ Wei Li,⁹ Geoffrey Liu,¹⁰ Caicun Zhou^{11 1}UC San Diego Moores Cancer Center, San Diego, CA, USA; ²Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; ³University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, CA, USA; ⁴Kindai University Faculty of Medicine, Osaka, Japan; ⁵Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China; ⁶McGill University Health Centre, Montreal, QC, Canada; ⁷Léon Bérard Cancer Center, Lyon, France; ⁸Nuvation Bio Inc., New York, NY, USA; ⁹Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China; ¹⁰Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, ON, Canada; ¹¹Shanghai East Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

Presented at the American Association for Cancer Research (AACR) Annual Meeting | April 17–22, 2026 | San Diego, CA, USA